SK282448B6 - Použitie derivátov cystínu - Google Patents

Použitie derivátov cystínu Download PDF

Info

Publication number: SK282448B6
Authority: SK; Slovakia
Prior art keywords: butyl; methylpropyl; restenosis; methylbutyl; propyl
Prior art date: 1995-03-14

Application number

SK1207-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK120797A3 (en

Inventor

H�Kan Bergstrand

Knut Petterson

Christer Westerlund

Original Assignee

Astra Aktiebolag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-14

Filing date

1996-03-12

Publication date

2002-02-05

1996-03-12 Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag

1998-02-04 Publication of SK120797A3 publication Critical patent/SK120797A3/sk

2002-02-05 Publication of SK282448B6 publication Critical patent/SK282448B6/sk

Links

LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical class C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 title claims abstract description 7
208000037803 restenosis Diseases 0.000 claims abstract description 20
150000003839 salts Chemical class 0.000 claims abstract description 15
238000011282 treatment Methods 0.000 claims abstract description 12
238000002360 preparation method Methods 0.000 claims abstract description 11
238000011321 prophylaxis Methods 0.000 claims abstract description 8
239000003814 drug Substances 0.000 claims abstract description 6
-1 n-octyl Chemical group 0.000 claims description 26
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 7
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 6
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 6
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 6
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 5
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
210000001124 body fluid Anatomy 0.000 claims description 3
239000010839 body fluid Substances 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
125000001424 substituent group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 23
229940126062 Compound A Drugs 0.000 description 20
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 20
239000000243 solution Substances 0.000 description 14
239000003826 tablet Substances 0.000 description 10
208000034827 Neointima Diseases 0.000 description 9
239000000443 aerosol Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 7
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
239000000843 powder Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000008101 lactose Substances 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000006378 damage Effects 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
238000011161 development Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000008692 neointimal formation Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
239000004147 Sorbitan trioleate Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
229940112141 dry powder inhaler Drugs 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002664 inhalation therapy Methods 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229940100688 oral solution Drugs 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000019337 sorbitan trioleate Nutrition 0.000 description 2
229960000391 sorbitan trioleate Drugs 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004158 L-cystine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229950009789 cetomacrogol 1000 Drugs 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
LMMBGFRHSXBSQC-UHFFFAOYSA-N dichloro(difluoro)methane;1,1-dichloro-1,2,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)Cl.FC(F)(F)C(F)(Cl)Cl LMMBGFRHSXBSQC-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940124274 edetate disodium Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229940041476 lactose 100 mg Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229960002969 oleic acid Drugs 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
229960003912 probucol Drugs 0.000 description 1
239000003380 propellant Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
SNYDMZJXWYXCKT-UHFFFAOYSA-M sodium propane-1,2,3-triol benzoate Chemical compound [Na+].OCC(O)CO.[O-]C(=O)c1ccccc1 SNYDMZJXWYXCKT-UHFFFAOYSA-M 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
JVFFWGJAAQAIBS-UHFFFAOYSA-K trisodium 2,2-dioctyl-3-sulfonatobutanedioate Chemical compound [Na+].C(CCCCCCC)C(C(C(=O)[O-])S(=O)(=O)[O-])(C(=O)[O-])CCCCCCCC.[Na+].[Na+] JVFFWGJAAQAIBS-UHFFFAOYSA-K 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000811 xylitol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SK1207-97A 1995-03-14 1996-03-12 Použitie derivátov cystínu SK282448B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9500897A SE9500897D0 (sv)	1995-03-14	1995-03-14	The pharmacological use of certain cystine derivatives
PCT/SE1996/000320 WO1996028149A1 (en)	1995-03-14	1996-03-12	The pharmacological use of certain cystine derivatives

Publications (2)

Publication Number	Publication Date
SK120797A3 SK120797A3 (en)	1998-02-04
SK282448B6 true SK282448B6 (sk)	2002-02-05

Family

ID=20397536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1207-97A SK282448B6 (sk)	1995-03-14	1996-03-12	Použitie derivátov cystínu

Country Status (24)

Country	Link
US (1)	US5883126A (cs)
EP (1)	EP0814798A1 (cs)
JP (1)	JPH11501916A (cs)
KR (1)	KR19980703055A (cs)
CN (1)	CN1183718A (cs)
AR (1)	AR002716A1 (cs)
AU (1)	AU701287B2 (cs)
BR (1)	BR9607225A (cs)
CA (1)	CA2214831A1 (cs)
CZ (1)	CZ288219B6 (cs)
EE (1)	EE03382B1 (cs)
HU (1)	HUP9801985A3 (cs)
IL (1)	IL117465A (cs)
IS (1)	IS4554A (cs)
NO (1)	NO974143L (cs)
NZ (1)	NZ303781A (cs)
PL (1)	PL183234B1 (cs)
SE (1)	SE9500897D0 (cs)
SK (1)	SK282448B6 (cs)
TR (1)	TR199700945T1 (cs)
TW (1)	TW385249B (cs)
UA (1)	UA42830C2 (cs)
WO (1)	WO1996028149A1 (cs)
ZA (1)	ZA961749B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6007819A (en) *	1995-10-17	1999-12-28	Dovetail Technologies, Inc.	Methods of inducing immunity using low molecular weight immune stimulants
DE19821625C1 (de) *	1998-05-15	2000-01-05	Merck Patent Gmbh	Pharmazeutische Zubereitung
SE9900438D0 (sv) *	1999-02-10	1999-02-10	Astra Ab	The pharmacological use of certian cystine derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR8205M (cs) *	1968-12-20	1970-09-14
US3878305A (en) *	1972-05-25	1975-04-15	Procter & Gamble	Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids
FR2289179A1 (fr) *	1974-10-28	1976-05-28	Morelle Jean	Sels metalliques de lipoaminoacides
US3952115A (en) *	1975-04-02	1976-04-20	The Procter & Gamble Company	Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters
GB2097256B (en) *	1981-04-02	1985-05-30	Morelle Jean V	Compositions containing n-butyryl alphaaminoacids
FR2503151A1 (fr) *	1981-04-02	1982-10-08	Morelle Jean	Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux
US4708965A (en) *	1985-09-16	1987-11-24	Morgan Lee R	Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives
US4827016A (en) *	1985-09-16	1989-05-02	Morgan Lee R	Method and compounds for reducing dermal inflammations
US4724239A (en) *	1985-09-16	1988-02-09	Morgan Lee R	Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine
JPS62195356A (ja) *	1986-02-20	1987-08-28	Seiwa Kasei:Kk	シスチン誘導体及びその塩
IL98310A (en) *	1990-06-08	1996-08-04	Astra Ab	Pharmaceutical compositions comprising cystine derivatives
TW221376B (cs) *	1990-06-28	1994-03-01	Astra Ab
IT1249650B (it) *	1991-05-29	1995-03-09	Poli Ind Chimica Spa	N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
SE9103572D0 (sv) *	1991-11-29	1991-11-29	Astra Ab	Organic salts of n,n'-diacetyl cystine
EP0746202A4 (en) *	1992-01-06	1997-06-25	Health Maintenance Programs	COMPOSITION CONTAINING A PHARMACEUTICALLY ACTIVE ANTI-OXIDANT AND METHOD FOR USE IN THE PREVENTION AND TREATMENT OF RESTENOSIS AFTER ANGIOPLASTY
DE4224670A1 (de) *	1992-07-25	1994-01-27	Boehringer Mannheim Gmbh	Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker

1995
- 1995-03-14 SE SE9500897A patent/SE9500897D0/xx unknown
1996
- 1996-02-16 TW TW085101975A patent/TW385249B/zh not_active IP Right Cessation
- 1996-03-04 ZA ZA961749A patent/ZA961749B/xx unknown
- 1996-03-12 SK SK1207-97A patent/SK282448B6/sk unknown
- 1996-03-12 TR TR97/00945T patent/TR199700945T1/xx unknown
- 1996-03-12 AU AU50185/96A patent/AU701287B2/en not_active Ceased
- 1996-03-12 EP EP96906992A patent/EP0814798A1/en not_active Withdrawn
- 1996-03-12 UA UA97105046A patent/UA42830C2/uk unknown
- 1996-03-12 JP JP8527519A patent/JPH11501916A/ja active Pending
- 1996-03-12 CN CN96193717A patent/CN1183718A/zh active Pending
- 1996-03-12 EE EE9700229A patent/EE03382B1/xx not_active IP Right Cessation
- 1996-03-12 US US08/619,681 patent/US5883126A/en not_active Expired - Fee Related
- 1996-03-12 KR KR1019970706464A patent/KR19980703055A/ko not_active Ceased
- 1996-03-12 CA CA002214831A patent/CA2214831A1/en not_active Abandoned
- 1996-03-12 BR BR9607225A patent/BR9607225A/pt not_active Application Discontinuation
- 1996-03-12 WO PCT/SE1996/000320 patent/WO1996028149A1/en not_active Ceased
- 1996-03-12 CZ CZ19972804A patent/CZ288219B6/cs not_active IP Right Cessation
- 1996-03-12 HU HU9801985A patent/HUP9801985A3/hu unknown
- 1996-03-13 IL IL11746596A patent/IL117465A/xx not_active IP Right Cessation
- 1996-03-13 AR ARP960101738A patent/AR002716A1/es unknown
- 1996-03-29 NZ NZ303781A patent/NZ303781A/en unknown
- 1996-03-29 PL PL96322328A patent/PL183234B1/pl unknown
1997
- 1997-08-27 IS IS4554A patent/IS4554A/is unknown
- 1997-09-09 NO NO974143A patent/NO974143L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU701287B2 (en)	1999-01-21
US5883126A (en)	1999-03-16
EP0814798A1 (en)	1998-01-07
SE9500897D0 (sv)	1995-03-14
MX9706825A (es)	1997-11-29
UA42830C2 (uk)	2001-11-15
BR9607225A (pt)	1998-07-07
AU5018596A (en)	1996-10-02
CZ280497A3 (cs)	1998-01-14
SK120797A3 (en)	1998-02-04
WO1996028149A1 (en)	1996-09-19
IL117465A (en)	2000-07-26
TR199700945T1 (xx)	1998-02-21
KR19980703055A (ko)	1998-09-05
CA2214831A1 (en)	1996-09-19
TW385249B (en)	2000-03-21
NO974143D0 (no)	1997-09-09
NZ303781A (en)	2001-03-30
AR002716A1 (es)	1998-04-29
PL322328A1 (en)	1998-01-19
HUP9801985A2 (hu)	1998-12-28
CZ288219B6 (en)	2001-05-16
ZA961749B (en)	1996-09-16
EE03382B1 (et)	2001-04-16
EE9700229A (et)	1998-04-15
CN1183718A (zh)	1998-06-03
NO974143L (no)	1997-09-09
IS4554A (is)	1997-08-27
JPH11501916A (ja)	1999-02-16
HUP9801985A3 (en)	2000-07-28
IL117465A0 (en)	1996-07-23
PL183234B1 (pl)	2002-06-28

Publication	Publication Date	Title
US6277882B1 (en)	2001-08-21	Utilization of alkyl hydrogen fumarates for treating psoriasis, psoriatic arthritis, neurodermatitis and regional enteritis
ES2244103T3 (es)	2005-12-01	Remedio para enfermedades neurodegenerativas.
BRPI0616276A2 (pt)	2011-06-14	composiÇço farmacÊutica de liberaÇço controlada de cloridrato de venlafaxina e processo de preparaÇço da mesma
AU701287B2 (en)	1999-01-21	The pharmacological use of certain cystine derivatives
KR20210137484A (ko)	2021-11-17	캡시드 조립 조절제 고체 제형
MXPA97006825A (en)	1998-07-03	The pharmacological use of certain derivatives of cist
HK1017987A (en)	1999-12-10	The pharmacological use of certain cystine derivatives
US20060287353A1 (en)	2006-12-21	Method for preventing or treating ischemia-or hemorrhage-induced brain damage using a macrolide compound
JP2609882B2 (ja)	1997-05-14	脱髄性疾患治療薬
WO2000047201A1 (en)	2000-08-17	The pharmacological use of certain cystine derivatives
JPH03287537A (ja)	1991-12-18	抗動脈硬化症剤
WO2001097798A1 (en)	2001-12-27	Method for the prevention or reduction of cardiovascular events associated with coronary intervention
JP2002536326A (ja)	2002-10-29	冠状動脈インターベンションに伴う心臓血管事象の予防または軽減方法
CA2361581A1 (en)	2000-08-10	Method for the prevention or reduction of cariovascular events associated with coronary intervention
WO2006104399A1 (en)	2006-10-05	Copper antagonist compositions